E 3620

Drug Profile

E 3620

Alternative Names: E3620

Latest Information Update: 06 Aug 2007

Price : $50

At a glance

  • Originator Eisai Co Ltd
  • Class Antiemetics; Benzamides; Gastrokinetics; Irritable bowel syndrome therapies
  • Mechanism of Action Serotonin 3 receptor antagonists; Serotonin 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Irritable bowel syndrome; Non-ulcer dyspepsia

Most Recent Events

  • 06 Aug 2007 Discontinued - Phase-II for Non-ulcer dyspepsia in Japan (PO)
  • 06 Aug 2007 Discontinued - Phase-II for Irritable bowel syndrome in Japan (PO)
  • 19 Jun 2002 This compound is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top